GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sihuan Pharmaceutical Holdings Group Ltd (OTCPK:SHPHF) » Definitions » Accounts Payable & Accrued Expense

Sihuan Pharmaceutical Holdings Group (Sihuan Pharmaceutical Holdings Group) Accounts Payable & Accrued Expense : $197.9 Mil (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Sihuan Pharmaceutical Holdings Group Accounts Payable & Accrued Expense?

Sihuan Pharmaceutical Holdings Group's quarterly accounts payable & accrued expense declined from Dec. 2022 ($210.5 Mil) to Jun. 2023 ($202.6 Mil) and declined from Jun. 2023 ($202.6 Mil) to Dec. 2023 ($197.9 Mil).

Sihuan Pharmaceutical Holdings Group's annual accounts payable & accrued expense increased from Dec. 2021 ($174.9 Mil) to Dec. 2022 ($210.5 Mil) but then declined from Dec. 2022 ($210.5 Mil) to Dec. 2023 ($197.9 Mil).

Sihuan Pharmaceutical Holdings Group Accounts Payable & Accrued Expense Historical Data

The historical data trend for Sihuan Pharmaceutical Holdings Group's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sihuan Pharmaceutical Holdings Group Accounts Payable & Accrued Expense Chart

Sihuan Pharmaceutical Holdings Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Accounts Payable & Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 109.43 143.46 174.91 210.51 197.86

Sihuan Pharmaceutical Holdings Group Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Accounts Payable & Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 174.91 238.81 210.51 202.60 197.86

Sihuan Pharmaceutical Holdings Group Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Sihuan Pharmaceutical Holdings Group (Sihuan Pharmaceutical Holdings Group) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sihuan Pharmaceutical Holdings Group Ltd (OTCPK:SHPHF) » Definitions » Accounts Payable & Accrued Expense
Comparable Companies
HKSE:01681 HKSE:01349 HKSE:02877 HKSE:06896 HKSE:03613 HKSE:02348 HKSE:01558 HKSE:01061 HKSE:02552 HKSE:02633 XTER:MRK ZTS NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA XSWX:SDZ NBIX SZSE:000538 NSE:DIVISLAB
Traded in Other Exchanges
00460:Hong Kong
Address
Zhubang 2000 Business Centre, 22nd Floor, Building 4, West Balizhuang, Chaoyang District, Beijing, CHN, 100025
Website
https://www.sihuanpharm.com
Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the research & development and the manufacture & sale of pharmaceutical products. Its portfolio comprises products for diseases related to the cardio-cerebral vascular (CCV) system, Digestive System, Anti-Infective, metabolism, Respiratory, Neurology, and Others. The group has three reportable segments: the medical aesthetic products segment including the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skincare, and others to provide non- or minimally invasive medical aesthetics comprehensive solutions; the innovative medicine and other medicine segments; and the generic medicine segment.